How Bay Area's Depomed and Its CEO Has Avoided Being Taken Over So Far
It’s good that Depomed Inc. CEO James Schoeneck loved to play strategy board games as a child, because in navigating the past few years for the pharmaceutical company, Schoeneck’s strategic thinking has been amply tested.
“It’s a big board game — but there’s no rules on the inside of the box,” he said.
A member of Depomed’s board since 2007 and president and CEO since 2011, the pharmaceutical industry veteran has guided the publicly traded company through a period of significant growth: Depomed increased in size from 67 employees to its current 450.
“It’s a big board game — but there’s no rules on the inside of the box,” he said.
A member of Depomed’s board since 2007 and president and CEO since 2011, the pharmaceutical industry veteran has guided the publicly traded company through a period of significant growth: Depomed increased in size from 67 employees to its current 450.